| Cancer statistics, 2012 | Ca-A Cancer Journal for Clinicians | 2012 | 9.4K |
| The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data | Cancer Discovery | 2012 | 8.6K |
| The blockade of immune checkpoints in cancer immunotherapy | Nature Reviews Cancer | 2012 | 8.1K |
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Lancet Oncology, The | 2012 | 4K |
| The immune contexture in human tumours: impact on clinical outcome | Nature Reviews Cancer | 2012 | 2.8K |
| Accessories to the crime: functions of cells recruited to the tumor microenvironment | Cancer Cell | 2012 | 2.7K |
| Radiomics: extracting more information from medical images using advanced feature analysis | European Journal of Cancer | 2012 | 2.3K |
| Cancer treatment and survivorship statistics, 2012 | Ca-A Cancer Journal for Clinicians | 2012 | 2.1K |
| Metabolic reprogramming: a cancer hallmark even warburg did not anticipate | Cancer Cell | 2012 | 2.1K |
| Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Lancet Oncology, The | 2012 | 1.7K |
| Molecular mechanisms of cisplatin resistance | Oncogene | 2012 | 1.6K |
| Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes | Journal of Clinical Oncology | 2012 | 1.6K |
| Antibody therapy of cancer | Nature Reviews Cancer | 2012 | 1.5K |
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Lancet Oncology, The | 2012 | 1.4K |
| Cancer immunotherapy via dendritic cells | Nature Reviews Cancer | 2012 | 1.4K |
| Mitochondria and cancer | Nature Reviews Cancer | 2012 | 1.3K |
| Intra-tumour heterogeneity: a looking glass for cancer? | Nature Reviews Cancer | 2012 | 1.3K |
| Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma | Cancer Cell | 2012 | 1.3K |
| Nutrition and physical activity guidelines for cancer survivors | Ca-A Cancer Journal for Clinicians | 2012 | 1.3K |
| Global cancer transitions according to the Human Development Index (2008-2030): a population-based study | Lancet Oncology, The | 2012 | 1.3K |
| Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years | Journal of Clinical Oncology | 2012 | 1.3K |
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009 | Neuro-Oncology | 2012 | 1.2K |
| Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma | Cancer Cell | 2012 | 1.2K |
| Deconvoluting the context-dependent role for autophagy in cancer | Nature Reviews Cancer | 2012 | 1.2K |
| Inference of population splits and mixtures from genome-wide allele frequency data | PLoS Genetics | 2012 | 1.2K |
